1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 68, 394–424 (2018).
2. Horta, M. & Cunha, T. M. Endometrial cancer. in Medical Radiology 179–208 (Springer Verlag, 2019). doi:10.1007/174_2016_84.
3. Torre, L. A. et al. Global cancer statistics, 2012. CA. Cancer J. Clin. 65, 87–108 (2015).
4. Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 70, 313– 313 (2020).
5. Yamagami, W. et al. Clinical statistics of gynecologic cancers in Japan. Journal of gynecologic oncology vol. 28 e32 (2017).
6. HOME：[国立がん研究センター がん登録・統計]. https://ganjoho.jp/reg_stat/index.html.
7. Bokhman, J. V. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 15, 10–17 (1983).
8. Soslow, R. A. et al. Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists. Int. J. Gynecol. Pathol. 38, S64–S74 (2019).
9. Braun, M. M., Overbeek-Wager, E. A. & Grumbo, R. J. Diagnosis and management of endometrial cancer. Am. Fam. Physician 93, 468–474 (2016).
10. Murali, R., Soslow, R. A. & Weigelt, B. Classification of endometrial carcinoma: More than two types. The Lancet Oncology vol. 15 (2014).
11. Raffone, A. et al. TCGA molecular groups of endometrial cancer: Pooled data about prognosis. Gynecologic Oncology vol. 155 374–383 (2019).
12. Getz, G. et al. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67–73 (2013).
13. Talhouk, A. et al. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer 123, 802–813 (2017).
14. Kommoss, S. et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann. Oncol. 29, 1180–1188 (2018).
15. Urick, M. E. & Bell, D. W. Clinical actionability of molecular targets in endometrial cancer. Nature Reviews Cancer vol. 19 510–521 (2019).
16. Gordhandas, S. et al. Clinicopathologic features of endometrial cancer with mismatch repair deficiency. Ecancermedicalscience 14, 1061 (2020).
17. Macdonald, N. D. et al. Frequency and Prognostic Impact of Microsatellite Instability in a Large Population-based Study of Endometrial Carcinomas 1. CANCER RESEARCH vol. 60 (2000).
18. Ono, R. et al. Dedifferentiated endometrial carcinoma could be a target for immune checkpoint inhibitors (Anti PD-1/PD-L1 antibodies). Int. J. Mol. Sci. 20, (2019).
19. Chen, Q., Li, T. & Yue, W. Drug response to PD-1/PD-l1 blockade: Based on biomarkers. OncoTargets and Therapy vol. 11 4673–4683 (2018).
20. Wang, Q., Liu, F. & Liu, L. Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis. Medicine (United States) vol. 96 (2017).
21. Pasanen, A., Loukovaara, M. & Bützow, R. Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma. Mod. Pathol. 33, 1443–1452 (2020).
22. Kim, S. R. et al. Does MMR status in endometrial cancer influence response to adjuvant therapy? Gynecol. Oncol. 151, 76–81 (2018).
23. Crumley, S. et al. Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes. Mod. Pathol. 32, 396–404 (2019).
24. Pasanen, A. et al. PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences across Histologic and TCGA-based Molecular Subgroups. Am. J. Surg. Pathol. 44, 174–181 (2020).
25. Shikama, A. et al. Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas. Gynecol. Oncol. 140, 226–233 (2016).
26. Alkushi, A. et al. Interpretation of p53 Immunoreactivity in Endometrial Carcinoma: Establishing a Clinically Relevant Cut-Off Level. Int. J. Gynecol. Pathol. 23, 129–137 (2004).
27. Köbel, M. et al. Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility. Int. J. Gynecol. Pathol. 38, S123– S131 (2019).
28. Yamashita, H. et al. Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer. Oncotarget 9, 5652–5664 (2018).
29. Engerud, H. et al. High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. Gynecol. Oncol. 157, 260–267 (2020).
30. Marinelli, O. et al. The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies. Frontiers in Oncology vol. 9 (2019).
31. Singh, N. et al. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. J. Pathol. 250, 336–345 (2020).
32. Shim, H. S. et al. Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung. J. Thorac. Oncol. 10, 1156–1162 (2015).
33. Galuppini, F. et al. Tumor mutation burden: From comprehensive mutational screening to the clinic. Cancer Cell International vol. 19 209 (2019).
34. Yu, X. Y. et al. Correlation and prognostic significance of PD-L1 and P53 expression in resected primary pulmonary lymphoepithelioma-like carcinoma. J. Thorac. Dis. 10, 1891–1902 (2018).
35. Abdulfatah, E. et al. Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: Towards early personalized patient management. Gynecol. Oncol. 154, 467–474 (2019).
論文の公開元へ
